Natixis Neogenomics Inc Transaction History
Natixis
- $16 Billion
- Q4 2024
A detailed history of Natixis transactions in Neogenomics Inc stock. As of the latest transaction made, Natixis holds 150 shares of NEO stock, worth $1,489. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 150
-0.0%
Holding current value
$1,489
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NEO
# of Institutions
282Shares Held
124MCall Options Held
751KPut Options Held
107K-
Black Rock Inc. New York, NY19.7MShares$195 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$141 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.53MShares$64.8 Million0.07% of portfolio
-
Janus Henderson Group PLC London, X06.17MShares$61.2 Million0.05% of portfolio
-
Brown Advisory Inc6.16MShares$61.1 Million0.13% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.25B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...